Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 125Myelodysplastic Syndromes 118Precursor Cell Lymphoblastic Leukemia-Lymphoma 107Leukemia 86Leukemia, Lymphocytic, Chronic, B-Cell 78Hodgkin Disease 78Lymphoma, Non-Hodgkin 73Lymphoma 73Multiple Myeloma 66Myeloproliferative Disorders 57Graft vs Host Disease 52Lymphoma, Follicular 51Leukemia, Myeloid, Accelerated Phase 50Lymphoma, Mantle-Cell 49Lymphoma, Large B-Cell, Diffuse 49Leukemia, Myelomonocytic, Chronic 48Congenital Abnormalities 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Hematologic Neoplasms 45Lymphoma, B-Cell, Marginal Zone 44Leukemia, Myeloid, Chronic-Phase 44Burkitt Lymphoma 41Primary Myelofibrosis 40Blast Crisis 39Neoplasms, Plasma Cell 36Lymphoma, Large-Cell, Immunoblastic 34Waldenstrom Macroglobulinemia 26Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Myelodysplastic-Myeloproliferative Diseases 24Anemia, Refractory, with Excess of Blasts 24

Interventions

venetoclax 6fludarabine phosphate 5ibrutinib 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2pirtobrutinib 1pembrolizumab 1obinutuzumab 1carmustine, poliferprosan 20 drug combination 1acalabrutinib 1Sirolimus 1Nivolumab 1Maintenance 1Etoposide 1Dexamethasone 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Bortezomib 1Bendamustine Hydrochloride 1Atorvastatin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Chromosome 17 deletion × Tacrolimus × Other hematologic neoplasm × Clear all
NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡